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ABSTRACT
Introduction: Although various studies have been published regarding the treatment of 
chronic hepatitis C (CHC) with peginterferon (Peg-IFN) and ribavirin, little is known 
regarding the real impact of gender on the characteristics that influence the effectiveness and 
safety of antiviral treatment for CHC patients. The objective of this study was to evaluate the 
influence of gender on HCV treatment outcomes. Methods: A retrospective analytical study 
was conducted among selected carriers of CHC genotype 1, who were treated with Peg-IFN 
α-2b at a dose of 1.5 µg/kg or Peg-IFN α-2a at a dose of 180 µg/week plus a ribavirin dose 
of  1,000-1,250 mg/day, according to weight, between 2001 and 2007. Results: Among 181 
patients undergoing treatment, the mean age was 46.4 ± 11.0 years and 46% were women. At 
baseline, 32% of the patients had advanced fibrosis (F3-F4 Scheuer), and 83% of the subjects 
had viral load > 400,000 IU/ml, without significant difference between the genders (p = 
0.428 and p = 0.452, respectively). When compared with men, women had higher incidence 
of many adverse events such as anemia (p < 0.001) and higher need for dose reduction, for 
both Peg-IFN (p = 0.004) and ribavirin (p = 0.006). However, the rate of sustained virological 
response (SVR) did not differ between the genders: 45% (female) vs 41% (male); p=0.464. 
Conclusions: This study suggests that women and men react differently to combined therapy, 
especially in relation to the incidence of adverse events and the need for dose modification. 
Nevertheless, these differences do not influence the SVR rate. 
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RESUMO
Introdução: Apesar dos vários estudos publicados a respeito do tratamento da hepatite C 
crônica (CHC) com Peg-Interferon (Peg-IFN) e ribavirina, se desconhece o real impacto do 
gênero sobre as características que influenciam a eficácia e a segurança da terapia antiviral em 
portadores de CHC. O objetivo deste estudo foi avaliar a influência do gênero no tratamento 
da CHC. Métodos: Foi realizado um estudo analítico retrospectivo de portadores de CHC 
genótipo 1 tratados com Peg-IFN α-2b na dose de 1,5µg/kg ou Peg-IFN α-2a na dose de180µg/
sem associado à ribavirina  1.000-1.250 mg/dia, de acordo com o peso, entre 2001 e 2007. 
Resultados: Entre 181 pacientes submetidos ao tratamento, a média de idade foi de 46,4±11,0 
anos e 46% eram mulheres. No pré-tratamento, 32% dos pacientes apresentavam fibrose 
avançada (F3-F4 Scheuer), e 83% dos indivíduos apresentavam carga viral >400.000IU/mL, 
sem diferença significativa entre os gêneros (p=0,428 e p=0,452, respectivamente). Quando 
comparadas aos homens, as mulheres exibiram maior incidência de eventos adversos como 
anemia (p<0,001) e maior necessidade de redução de dose tanto do Peg-IFN (p=0,004) 
quanto da ribavirina (p=0,006). Entretanto, as taxas de resposta virológica sustentada (RVS) 
não diferiram entre os gêneros (45% (mulheres) . vs 41% (homens); p=0,464). Conclusões: 
Este estudo sugere que homens e mulheres reagem à terapia combinada de forma diferente, 
especialmente com relação aos eventos adversos e à necessidade de modificação de dose. No 
entanto, essas diferenças não influenciam as taxas de RVS.
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Hepatitis C virus (HCV) infection remains 
highly prevalent, and it is estimated that 170 million 
people worldwide are chronic carriers1. Despite 
recent advances, few studies have evaluated the 
characteristics of HCV infection in women. Some 
authors have demonstrated that women have less 
altered hepatic biochemical tests and lower rates of 
fibrotic progression2-5. It is believed that these findings 
are related to the protective effects of estrogen, 
which possesses anti-fibrotic activity6 and blocks 
fibrogenesis in the hepatic stellate cells7. The idea 
that estrogen has a protective role was also suggested 
by a study on chronic HCV patients that observed 
a greater chance of progression to hepatic cirrhosis 
among asymptomatic women older than 50 years 
of age8. Furthermore, that study demonstrated that 
female patients with chronic hepatitis had a lower 
risk of developing hepatocarcinoma than did men8. 
The menopause appears to be associated with an 
accelerated rate of fibrotic progression, and hormone 
replacement therapy may minimize this effect6.
Spontaneous clearance of HCV infection appears 
to be more frequent among women after acute 
infection9-11. It is possible that the higher prevalence 
of viral clearance among women is associated with 
immunological factors12 and genetics (in particular, 
the HLA DRB1*0113, HLA-Bw35, HLA-DRB1*814 
and GG genotypes15). 
To date, the only study that evaluated the influence 
of gender on the treatment for chronic hepatitis C 
genotype 1 concluded that the response to combined 
therapy with pegylated interferon alpha (Peg-IFN) 
and ribavirin (RBV) was poorer among female than 
among male hepatitis C-infected patients aged 50 years 
or older, irrespective of compliance (32% vs 63%)16. 
Previously, Hayashi et al assessed gender importance 
in relation to the response to conventional interferon 
alpha treatment (IFN) alone and concluded that 
women younger than 40 years of age had higher 
rates of sustained virological response (SVR) than 
did men (75% vs 33%)17.
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METHODS
It may be intuitively concluded that women suffering from 
chronic hepatitis C have specific characteristics that potentially 
affect the course and outcome of antiviral therapy. However, despite 
several published studies on the treatment of hepatitis C with 
Peg-IFN and RBV, little is known about the real impact of gender on 
the characteristics that influence the efficacy and safety of treatment 
for chronic hepatitis C. Thus, this study aimed to evaluate the 
influence of gender on relevant pre-treatment characteristics of HCV 
patients, as well as the impact of gender on the tolerability profile and 
efficacy of combination therapy with Peg-IFN and RBV.
Patients
This cross-sectional study was carried out in a single tertiary care 
centre (Hepatitis Section, Hospital São Paulo, Brazil) and included 
consecutive adult naïve patients with biopsy-proven chronic hepatitis 
C genotype 1, who were treated with Peg-IFN and RBV between 
January 2001 and December 2007. HCV infection was defined as a 
positive HCV RNA finding from PCR (> 50 IU/ml). Patients with 
HBV and/or HIV coinfection, end-stage renal disease or incomplete 
data on blood counts and/or liver panel were excluded. 
Methodology
Demographic, laboratory and other clinical variables were 
reviewed and extracted from medical records. Parenteral risk factor 
for HCV acquisition was defined as history of blood transfusion 
(if received before 1993) or injection drug use. Patients without 
parenteral risk factors were considered to present sporadic or 
unknown risk regarding the mode of infection. Patients with ethanol 
consumption greater than 50 g/day were considered to be alcohol 
abusers. Serum levels of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (AP) and gamma 
glutamyltransferase (GGT) were expressed as multiples of the upper 
limit of normalcy (ULN). The other parameters were expressed as 
absolute values. Only laboratory results performed within one month 
from the start of treatment were used for this study.
Histological analysis
All patients underwent liver biopsy irrespective of ALT levels. 
The liver biopsies were performed using a Tru-Cut 14-gauge biopsy 
needle, after the patients had given their written informed consent. The 
liver biopsy samples were fixed in formalin and embedded in paraffin. 
Slides were stained with hematoxylin and eosin, Masson’s trichrome, 
Perls’ Prussian blue, and Gomori reticulin. A single experienced 
pathologist who was unaware of the clinical data evaluated all the 
liver biopsy slides. Hepatitis C liver disease was classified according to 
Scheuer’s classification18. Fibrosis was staged as follows: 0= no fibrosis; 
1= enlarged, fibrotic portal tracts; 2= periportal or portal-portal septa 
but intact architecture; 3= fibrosis with architectural distortion but no 
obvious cirrhosis; 4= probable or definite cirrhosis. Portal/periportal 
necroinflammatory activity was graded on a scale ranging from 0-4: 
0= none or minimal; 1= portal inflammation; 2= mild limiting plate 
necrosis; 3= moderate limiting plate necrosis; 4= severe limiting plate 
necrosis. Advanced fibrosis was defined as stages 3 or 4, and significant 
periportal activity was defined as grades 3 or 4.
Treatment regimens and outcomes
All patients received Peg-IFN alpha-2a (180 µg/week) or 2b 
(1.5 µg/kg/week) and RBV at a dose of 1 or 1.25 g/day (dictated by 
weight less than or greater than 75 kg) for a minimum of 12 weeks 
and maximum of 48 weeks. The criteria for inclusion in the Peg-IFN 
treatment group were: age 18-70 years, HCV infection defined by 
the presence of positive HCV-RNA (> 50 IU/ml), as confirmed 
by qualitative polymerase chain reaction (PCR); HCV infection 
with genotype 1; liver biopsy performed not more than 24 months 
prior to inclusion, with Scheuer’s18 fibrosis stage and inflammatory 
grade ≥ 2.
The following were considered to be contraindications for 
treatment: current liver decompensation, immunosuppressive 
treatment within the last six months, associated liver diseases 
(especially autoimmune hepatitis) and other associated serious 
diseases such as systemic autoimmune disease, neoplasia, cardiac 
arrhythmias and ischemic vascular disease. 
Treatment was discontinued if HCV-RNA was detectable after six 
months of therapy. Patients were evaluated every two weeks during 
the first month and monthly thereafter. Complete blood count and 
serum biochemical parameters were assessed at least every 15 days 
during the first month, then monthly during treatment and post-
treatment follow-up at 3 and 6 months. 
Efficacy assessments
Sustained virological response was defined as undetectable 
HCV-RNA in a qualitative PCR evaluation (AMPLICOR® Hepatitis 
C Virus Test, version 2.0, Roche Molecular Systems, Branchburg, NJ, 
USA) performed six months after the end of treatment, using intention-
to-treat analysis. The lower limit of detection was 50 IU/ml.
Safety assessments
During the treatment, patients were seen at the outpatient clinics 
every two weeks for the first month and then monthly until the end 
of the treatment. A standardized questionnaire on adverse events was 
routinely applied to every patient, in order to document any of the 
following occurrences: flu-like symptoms, anemia (hemoglobin less 
than 10 g/dl), neutropenia (neutrophil count less than 1,500/mm3), 
thrombocytopenia (platelet count less than 50,000 platelets/mm3), 
psychiatric events (dizziness, panic attacks, depression, irritability), 
significant weight loss (weight loss exceeding 10% of baseline body 
weight), anorexia, nausea, insomnia, dermatitis or itching, alopecia, 
decreased visual acuity, diarrhea, dyspnea, bacterial infection and 
hypothyroidism (defined by TSH greater than 10 mIU/l).
Peg-IFN and RBV dose reduction and either treatment 
interruption or treatment suspension were also evaluated in order 
to evaluate tolerance to combined therapy.
Statistical analysis
Continuous variables were compared using Student’s t-test, or 
the Mann-Whitney U test when appropriate. Categorical variables 
were compared using Pearson’s chi-square test (c2) or Fisher’s exact 
test. A p value of less than 0.05 was considered statistically significant. 
A comparative analysis of all data was performed with regard to 
gender identity. Univariate and logistic regression analysis were used 
to identify variables associated with SVR. All tests were two-tailed 
and performed using the SPSS software version 15.0 (SPSS Inc., 
Chicago, Illinois, USA).
Ethical
The study protocol conformed to the ethical guidelines of the 
1975 Helsinki Declaration and was approved by our institutional 
review board.
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RESULTS
Characteristics of the patients
From January 2001 to December 2007, 181 patients were 
included in the study. Their mean age was 46.4 ± 11.0 years; 46% 
were women; 39% had a previous history of blood transfusion; and 
11% had a history of intravenous drug use. 
Compared with men (Table 1), women presented higher 
mean age (p = 0.003) and higher frequency of previous blood 
transfusion (p < 0.001). In contrast, histories of alcohol abuse 
(p < 0.001) and intravenous drug use (p < 0.001) were less common 
among women than among men. Despite similar BMI (p = 0.069), 
women showed lower mean baseline weight than presented by men 
(p < 0.001). No differences between the genders were identified 
in relation to biochemical and hematological parameters, 
except that women presented lower baseline neutrophil counts 
(p = 0.009). At baseline, 83% of all the patients had HCV viral loads 
greater than 400,000 IU/ml, but there was no statistically significant 
difference between genders (81% of women vs 85% of men; 
P = 0.452). Histologically, 32% of all the individuals had advanced 
fibrosis (F3 or F4), and 40% had evidence of significant periportal 
necroinflammatory activity (A3 or A4). No difference was 
identified with respect to fibrosis between men and women (35% 
of women vs 29% of  men; p = 0.428) or necroinflammatory activity 
(43% of women vs 38% of men; p = 0.533). 
Efficacy
Overall, 77 patients (43%) achieved SVR after combination 
therapy with Peg-IFN and RBV. Women received higher mean 
ribavirin doses per kg than did men (16.0 ± 2.9 vs 13.1 ± 2.1; 
p < 0.001). However, the proportions of individuals treated with Peg-
IFN alpha-2a was similar between genders (32.5% of women vs 37.8% 
of men, p = 0.064). In univariate analysis, advanced fibrosis, treatment 
suspension due to adverse events and thrombocytopenia were 
associated with treatment failure (Table 2). Nevertheless, in a multiple 
logistic regression model (Table 3), only suspension of treatment due 
to adverse events remained independently associated with failure to 
achieve SVR [odds ratio (OR): 9.006, 95% confidence interval (CI): 
1.096-74.026; p = 0.041]. SVR rates were similar between women and 
men (45% vs 41%, p = 0.464).
Safety
In general, women had a higher incidence of anemia (p < 
0.001), dizziness (p = 0.011), anorexia (p < 0.001), nausea (p = 
0.005), alopecia (p = 0.002), decreased visual acuity (p = 0.025), 
bacterial infection (p = 0.025) and hypothyroidism (p = 0.036), in 
relation to men. The adverse events are detailed for each cohort in 
Table 4. Women had higher rates of change in dosage of Peg-IFN 
(p = 0.004) and RBV (p = 0.006) during treatment, as demonstrated 
in Table 5. There were no significant differences between genders 
with regard to interruption (p = 0.190) or suspension (p = 0.383) 
of antiviral treatment. 
TABLE 1 - Baseline characteristics of 181 patients with chronic hepatitis C (genotype 1), treated with pegylated interferon 
and ribavirin, according to gender.
                                                                                        Gender 
 Total Female Male P‡
 n = 181 n = 83 n = 98 
Characteristics  (46%) (54%) 
Age (years)* 46.4 ± 11.0 (47.0) 49.0 ± 11.7 (51.0) 44.1 ± 10.0 (44.0) 0.003
Caucasian, n (%) 130 (71.8) 60 (72.3) 70 (71.4) 0.898
BMI (kg/m²)*# 25.6 ± 3.9 (25.3) 25.3 ± 4.2 (24.8) 25.8 ± 3.6 (25.6) 0.438
Weight (kg) 71.9 ± 1.0 (71.8) 64.1 ± 11.1 (62.5) 71.5 ± 12.3 (76.3) < 0.001
Alcohol abuse, n (%) 32 (17.7) 2 (2.4) 30 (31.6) < 0.001
Previous depression, n (%) 14 (7.7) 8 (9.6) 6 (6.1) 0.371
Mode of infection    
Transfusion, n (%) 71 (39.2) 47 (56.6) 24 (24.5) < 0.001
IV drug use, n (%) 20 (11.0) 1 (1.2) 19 (19.4) < 0.001
Sporadic/others, n (%) 90 (49.7) 35 (42.2) 55 (56.1) 0.061
AST (xULN)* 1.84 ± 1.08 (1.56) 2.02 ± 1.22 (1.63) 1.69 ± 0.93 (1.50) 0.108
ALT (xULN)* 2.41 ± 1.58 (2.01) 2.24 ± 1.58 (1.84) 2.55 ± 1.57 (2.12) 0.072
DB (mg/dl)* 0.38 ± 0.22 (0.30) 0.37 ± 0.20 (0.30) 0.38 ± 0.24 (0.30) 0.701
AP (xULN)* 0.71 ± 0.38 (0.66) 0.72 ± 0.29 (0.70) 0.70 ± 0.44 (0.63) 0.109
GGT (xULN)* 2.78 ± 2.86 (1.80) 2.67 ± 2.42 (1.79) 2.87 ± 3.20 (2.00) 0.660
Prothrombin activity (%)* 93.91 ± 10.35 (100) 93.2 ± 10.9 (100) 94.5 ± 9.8 (100) 0.400
Hemoglobin (g/dl)* 14.84 ± 1.46 (14.9) 13.89 ± 1.24 (14.0) 15.66 ± 1.10 (15.8) 0.141
Neutrophils (/mm³)* 3.177 ± 1.459 (3.008) 2.871 ± 1.124 (2.866) 3.438 ± 1.656 (3.130) 0.009
Platelets (/mm³)* 192.005 ± 67.437  196.578 ± 73.115  188.052 ± 62.231  0.400
 (190.000) (189.000) (190.500) 
VL ≥ 400,000 IU/ml, n (%)& 150 (82.9) 67 (80.7) 82 (84.7) 0.452
BMI: body mass index, #Available for 144 patients, *Mean ± standard deviation and median, IV: intravenous, ‡ Student’s t test, Mann-
Whitney test and c2 test when appropriate for comparison of groups, ULN: upper limit of normalcy. AST: aspartate aminotransferase, 
ALT: alanine aminotransferase, DB: direct bilirubin, AP: alkaline phosphatase, GGT: gamma-glutamyltransferase, VL: viral load, 
*Mean ± standard deviation and median.
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TABLE 2 - Univariate analysis on variables associated with treatment failure among patients with chronic hepatitis 
C (genotype 1), treated with pegylated interferon and ribavirin.
 SVR Not SVR P‡
Characteristics n = 77 (43%) n = 104 (57%) 
Female gender, n (%) 37 (48.1) 46 (44.2) 0.610
Age (years)* 44.8 ± 10.8 (46.0) 47.5 ± 11.1 (47.0) 0.107
Caucasian, n (%) 57 (74.0) 73 (70.2) 0.571
BMI (kg/m²)*# 24.9 ± 3.6 (25.3) 26.1 ± 4.0 (25.5) 0.069
Alcohol abuse, n (%) 14 (18.2) 18 (17.3) 0.879
Previous depression, n (%) 5 (6.5) 9 (8.7) 0.591
Advanced fibrosis, n (%) 18 (23.0) 40 (38.5) 0.028
Viral load ≥ 400,000 IU/ml, n (%)& 46 (79.3) 72 (85.7) 0.317
Peg-IFN alpha-2a, n (%) 26 (33.8) 38 (36.5) 0.700
Ribavirin dose mg/kg* 14.0 ± 2.9 (14.1) 14.2 ± 2.9 (13.8) 0.291
Peg-IFN dose modification, n (%) 8 (10.4) 10 (9.6) 0.863
Ribavirin dose modification, n (%) 15 (19.5) 23 (22.1) 0.667
Treatment interruption, n (%) 4 (5.2) 6 (5.8) 1.000
Treatment suspension due to AE, n (%) 3 (3.9) 19 (18.3) 0.005
Anemia, n (%) 23 (29.9) 30 (28.8)  0.881
Neutropenia, n (%) 20 (26.0) 22 (21.4) 0.469
Thrombocytopenia, n (%) 3 (3.9) 18 (17.3) 0.005
SVR: sustained virological response, BMI: body mass index, Peg-IFN: pegylated interferon, AE: adverse events, #Available 
in 144 patients, &Available in 142 patients, *Mean ± standard deviation and median; ‡Student’s t test, c2 test or Fisher’s 
exact test when appropriate for comparison of groups.
TABLE 3 - Factors associated with failure to achieve sustained virological response (SVR), according to multivariate analysis.
Factors Odds ratio 95% CI P value
Suspension of treatment due to AE 9.006 1.096 – 74.026 0.041
Body mass index 1.078 0.981 – 1.185 0.118
Thrombocytopenia 2.339 0.528 – 10.371 0.263
Age 1.005 0.973 – 1.739 0.747
Fibrosis stage 3 or 4 1.079 0.981 – 1.185 0.863
CI: confidence interval, AE: adverse events. 
TABLE 4 - Adverse events in patients with chronic hepatitis C (genotype 1) who were treated with pegylated interferon and 
ribavirin, according to gender.
                                         Gender 
 Total Female Male P‡
Adverse events n = 181 n = 83 n = 98 
Flu-like symptoms, n (%) 170 (93.9) 77 (92.8) 93 (94.9) 0.551
Anemia, n (%) 53 (29.3) 40 (48.2) 13 (13.3)  < 0.001
Neutropenia, n (%) 42 (23.3) 22 (26.5) 20 (20.6) 0.352
Thrombocytopenia, n (%) 21 (11.6) 9 (10.8) 12 (12.2) 0.478
Dizziness, n (%) 28 (15.5) 19 (22.9) 9 (9.2) 0.011
Panic attacks, n (%) 3 (1.7) 1 (1.2) 2 (2.0) 1.000
Depression, n (%) 65 (35.9) 34 (41.0) 31 (31.6) 0.192
Irritability, n (%) 48 (26.5) 20 (24.1) 28 (28.6) 0.497
Significant weight loss, n (%) 66 (36.5) 31 (37.3) 35 (35.7) 0.820
Anorexia, n (%) 36 (19.9) 26 (31.3) 10 (10.2) < 0.001
Nausea, n (%) 34 (18.8) 23 (27.7) 11 (11.2) 0.005
Insomnia, n (%) 25 (13.8) 12 (14.5) 13 (13.3) 0.817
Dermatitis or itching, n (%) 95 (52.5) 49 (59.0) 46 (46.9) 0.104
Alopecia, n (%) 24 (13.3) 18 (21.7) 6 (6.1) 0.002
Decreased visual acuity, n (%) 8 (4.4) 7 (8.4) 1 (1.0) 0.025
Diarrhea, n (%) 33 (18.2) 20 (24.1) 13 (13.3) 0.060
Dyspnea, n (%) 12 (6.6) 8 (9.6) 4 (4.1) 0.134
Infection, n (%) 35 (19.3) 22 (26.5) 13 (13.3) 0.025
Hypothyroidism, n (%) 12 (6.6) 9 (11.0) 3 (3.0) 0.036
Peg-IFN: pegylated interferon, ‡ Fisher’s exact test and c2 test when appropriate for comparison of groups.
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TABLE 5 - Modifications of pegylated interferon or ribavirin dose, and interruption or suspension of treatment, in patients with 
chronic hepatitis C (genotype 1), according to gender.
  Gender 
 Total Female Male P‡
 n = 181 n = 83 n = 98 
Modification of Peg-IFN dose, n (%) 18 (10.0) 14 (17.0) 4 (4.0) 0.004
Neutropenia, n (%)  5 (6.0) 2 (2.0) 0.250
Thrombocytopenia, n (%)  2 (2.4) 2 (2.0) 1.000
Significant weight loss, n (%)  3 (3.6) 0 (0.0) 0.095
Other adverse events, n (%)  4 (4.8) 0 (0.0) 0.042
Modification of ribavirin dose, n (%) 38 (21.0) 25 (30.0) 13 (13.0) 0.006
Anemia, n (%)  23 (27.7) 9 (9.2) 0.001
Other adverse events, n (%)  2 (2.4) 4 (4.1) 0.689
Treatment interruption due to AE, n (%) 10 (5.5) 7 (8.0) 3 (3.0) 0.190
Anemia, n (%)  4 (4.8) 0 (0.0) 0.042
Thrombocytopenia, n (%)  0 (0.0) 1 (1.0) 1.000
Other adverse events, n (%)  3 (3.6) 2 (2.0) 0.662
Treatment suspension due to AE, n (%) 42 (23.2) 12 (14.4) 10 (10.2) 0.383
Anemia, n (%)  1 (1.2) 1 (1.0) 1.000
Thrombocytopenia, n (%)  2 (2.4) 0 (0.0) 0.209
Other adverse events, n (%)  9 (10.8) 9 (9.2) 0.710
Peg-IFN: pegylated interferon, AE: adverse events, ‡Fisher’s exact test and c2 test when appropriate for comparison of groups.
DISCUSSION
Treatment with Peg-IFN and RBV for 48 weeks has been 
recommended for patients infected with HCV genotype 1, which is 
the most common variant not only in Brazil, but also in the United 
States and Europe19-20. Whereas SVR can be achieved in 81% to 
84% of patients infected with HCV genotype 2 or 3 after 24 weeks 
of combination therapy, the rate of SVR is much lower in patients 
with HCV genotype 1 infection, ranging from 34% to 52% after 
48 weeks of combination therapy with Peg-IFN and RBV21-23. In 
a retrospective study on Southern Brazilian patients with chronic 
hepatitis and HCV genotype 1 infection, SVR was achieved in only 
35.3% of patients (114/323), although this may have occurred 
because a large proportion of the patients presented advanced fibrosis 
(F3/F4 = 74%)24. However, previous Brazilian studies have 
demonstrated SVR rates of 44-52% in genotype 1 HCV infection 
among patients who were not enrolled in medical trials25-27. 
Improvements in the management of patients with chronic HCV 
genotype 1 infection are essential. Every effort needs to be directed 
towards an increase in SVR rates. A number of host and viral factors 
have been studied as possible predictors of treatment outcomes, such 
as gender, age, body weight, alcohol consumption, advanced fibrosis, 
basal viral load and treatment compliance. 
Despite a previous large analysis (n = 1744) on two trials 
involving standard IFN plus RBV therapy that showed a significant 
positive correlation between female gender and SVR (p < 0.004)28, 
no such difference has been confirmed in studies involving Peg-IFN 
plus RBV21-24,29-31. Kogure et al32 observed that among Asian patients, 
the SVR rate among females was significantly lower than the rate 
among males (17% vs 50%, p = 0.026). Furthermore, the SVR among 
older females was remarkably low (17.4%), compared with all the 
females included in the study (36%). Similarly, in another Asian 
study, Sezaki et al16 concluded that women older than 50 years of 
age had worse rates of SVR than did men (32% vs 63%, p = 0.016). 
In accordance to Western studies21-24,29-31, no differences in SVR have 
been shown between genders (p = 0.464), not even among patients 
older than 50 years of age (40% of women vs 38% of men; p = 0.859; 
data not shown). 
In all large prospective studies on Peg-IFN and RBV combination 
therapy, younger age correlated significantly with SVR and patients 
younger than 40–45 years showed the best response rates21,22,28. 
Recently, Reddy et al evaluated 569 genotype-1 patients who 
underwent Peg-IFN alpha-2a + RBV for 48 weeks, and demonstrated 
that the SVR rate among patients ≤ 50 years of age was greater than the 
rate among patients older than 50 years (52% vs 39%; p = 0.007)33.
Although high BMI has been previously identified as an 
independent risk factor for non-response to antiviral treatment 
with standard IFN plus RBV29, the results relating to pegylated 
presentation are controversial. While in both types of Peg-IFN 
combination therapy (alpha-2a/2b) with RBV, lower baseline body 
weight has formely been associated with achieving SVR21,22,34, this has 
not been confirmed in other large studies on HCV-infected patients 
in which multilogistic regression analyses including BMI and body 
weight were conducted30,35.
Alcohol consumption is possibly underestimated in most 
retrospective analyses. Hence, limited data are available on its 
impact on antiviral treatment outcome. In a large, prospective 
multicenter trial, it was observed that patients who drink alcohol 
discontinue therapy more often and therefore achieve lower SVR 
rates. Nevertheless, individuals with alcohol consumption who 
finished treatment had response rates comparable to those of non-
drinkers36.
The presence of advanced liver fibrosis and cirrhosis has long 
been accepted as associated with lower response rates to IFN-based 
treatment28. Furthermore, advanced fibrosis and cirrhosis have been 
shown to be major independent predictors of non-response37. In a 
recent study that evaluated the efficacy and safety of Peg-IFN alpha-2a 
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+ RBV in 341 genotype 1/4 patients, it was demonstrated that SVR 
rates decreased progressively from 60% in genotype 1/4 patients 
without advanced fibrosis to 51% in those with bridging fibrosis and 
33% in those with cirrhosis (p = 0.003)38.
Although HCV-related liver injury and disease progression 
have not been associated with viral load, HCV-RNA quantification 
before, during and after therapy is an essential tool for predicting 
treatment outcome. Low baseline viral load has been shown to be an 
independent predictor of SVR, regardless of genotype in numerous 
studies21,28,34,35. Initially, 800,000 IU/ml was recommended as the 
decision threshold for high vs low viremia39. However, subsequent 
data have suggested that a baseline level of 400,000 IU/ml is the most 
effective cutoff point between high and low likelihood of achieving 
SVR in genotype 1-infected patients40,41.
In addition to host and viral characteristics, certain treatment 
features may influence SVR, such as ribavirin dose and adherence. 
Nevertheless, no significant differences regarding SVR rates and 
tolerability have been demonstrated between the two available 
peginterferons31. A detailed analysis on the relationship between 
bodyweight and SVR suggests that ribavirin dose per kilogram 
may be the determining factor for the response among genotype 1 
patients, with a 40-50% increase in the likelihood of SVR for a 12-16 
mg/kg dose42. With regard to adherence, HCV-1-infected patients 
who can be maintained on > 80% of their Peg-IFN + RBV dosage for 
the duration of treatment in a clinical trial setting exhibit enhanced 
sustained response rates43. 
In this study, women had some favorable pretreatment-
related variables, including lower mean weight and less frequent 
history of alcohol abuse than shown by men. However, women 
presented higher mean age as a negative pretreatment predictor 
of SVR. Nevertheless, women and men presented equivalent BMI 
means, similar proportions of high viral load and comparable 
histological characteristics (advanced liver fibrosis and significant 
necroinflammatory activity). Despite similar SVR rates between 
genders, it was demonstrated that the women presented higher 
incidence of several adverse events and, consequently, Peg-IFN dose 
modifications were more frequent among women. Even though 
adherence per se was not evaluated in this study, no significant 
differences were observed between women and men with regard 
to interruption or suspension of antiviral therapy. This could reflect 
adequate management of adverse events, which made it possible to 
avoid a negative impact on SVR rate. 
Although some adverse events from combined therapy have 
previously been described in association with female gender, such 
as hypothyroidism44 and anemia45,46, most of the findings from this 
study have never been correlated with gender. The higher incidence 
of alopecia among women, for instance, could be associated 
with hypothyroidism44, but this relationship was not evidenced 
(p = 0,201; data not shown). 
Even though baseline hemoglobin levels and mean BMI were 
similar between genders, women weighed less than men did and 
thus received higher doses of RBV per kg. Although current data 
suggest that SVR increases linearly with ribavirin doses (which equate 
to > 10 mg/kg), there is also a simultaneous linear increase in the 
anemia rate (< 10 g/dl hemoglobin)42, which may possibly explain 
the higher incidence of anemia among women. It is well established 
that anemia can cause dizziness, asthenia and worsened quality of life, 
and may result in reduction, suspension or interruption of the RBV 
regimen47,48. In this study, anemia was the most common reason for 
RBV dose modification and treatment interruption among women; 
this probably reflects the higher incidence of anemia and its clinical 
manifestations such as dizziness. 
The limitations of this study include the possible selection bias 
due to retrospective data collection. Nevertheless, the data were 
collected from standardized medical records, and the treatment used 
has also been standardized by the Brazilian Public Health System, 
thus minimizing potential sources of bias. Secondly, the number of 
patients included was far smaller than in most published treatment 
studies, which have included 500-1,500 patients21-23. However, the 
characteristics of the patients included in the present study are 
comparable to those reported in the literature and represent a true 
picture of the chronic hepatitis C patients treated in Brazil. 
This study concluded that, while women and men exhibit similar 
clinical, histological and virological disease characteristics before 
beginning treatment, they react differently to combined therapy, 
especially with regard to the incidence of adverse events, which 
are more frequent among women. Furthermore, women required 
modifications to their antiviral therapy dose with greater frequency 
than men did, due to higher incidence of adverse events (particularly, 
anemia). Recognition of these features, which are unique to females, 
is fundamental for crafting a suitable approach towards treating these 
patients and optimizing the chances of cure for chronic hepatitis C 
infection. 
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